Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Cash from Financing Activities: 2011-2025

Historic Cash from Financing Activities for Capricor Therapeutics (CAPR) over the last 15 years, with Sep 2025 value amounting to $6,950.

  • Capricor Therapeutics' Cash from Financing Activities fell 99.99% to $6,950 in Q3 2025 from the same period last year, while for Sep 2025 it was $81.2 million, marking a year-over-year decrease of 14.43%. This contributed to the annual value of $152.8 million for FY2024, which is 497.23% up from last year.
  • As of Q3 2025, Capricor Therapeutics' Cash from Financing Activities stood at $6,950, which was down 64.50% from $19,580 recorded in Q2 2025.
  • Capricor Therapeutics' Cash from Financing Activities' 5-year high stood at $81.1 million during Q4 2024, with a 5-year trough of $3,895 in Q1 2023.
  • For the 3-year period, Capricor Therapeutics' Cash from Financing Activities averaged around $16.2 million, with its median value being $2.1 million (2024).
  • Per our database at Business Quant, Capricor Therapeutics' Cash from Financing Activities skyrocketed by 58,699.59% in 2024 and then slumped by 99.99% in 2025.
  • Capricor Therapeutics' Cash from Financing Activities (Quarterly) stood at $42,370 in 2021, then soared by 6,861.35% to $2.9 million in 2022, then soared by 685.45% to $23.2 million in 2023, then soared by 250.01% to $81.1 million in 2024, then plummeted by 99.99% to $6,950 in 2025.
  • Its Cash from Financing Activities was $6,950 in Q3 2025, compared to $19,580 in Q2 2025 and $50,354 in Q1 2025.